Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor: A report from the Children's Oncology Group

Eric J. Gratias, Jeffrey S. Dome, Lawrence J Jennings, Yueh Yun Chi, Jing Tian, James Anderson, Paul Grundy, Elizabeth A. Mullen, James I. Geller, Conrad V. Fernandez, Elizabeth J Perlman*

*Corresponding author for this work

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: The goal of this study was to analyze the association of copy number gain of 1q in favorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) within each tumor stage and with 1p and 16q copy number loss and/or loss of heterozygosity. Methods: Unilateral FHWTs from 1,114 patients enrolled in National Wilms Tumor Study-5 that were informative for 1p and 16q microsatellite markers (previously determined) and informative for 1q gain, 1p loss, and 16q loss using multiplex ligation-dependent probe amplification were analyzed. Results: Eight-year EFS was 86% (95% CI, 84% to 88%) for the entire cohort. Of 1,114 patients, 317 tumors (28%) displayed 1q gain. Eight-year EFS was 77% for those with 1q gain and 90% for those lacking 1q gain (P < .001). Eight-year OS was 88% for those with 1q gain and 96% for those lacking 1q gain (P < .001). Within each disease stage, 1q gain was associated with inferior EFS (stage I, 85% v 95%; P = .0052; stage II, 81% v 87%; P = .0775; stage III, 79% v 89%; P = .01; stage IV, 64% v 91%; P = .001). OS was significantly inferior in patients with stage I (P < .0015) and stage IV disease (P = .011). With multivariable analysis, 1q gain was associated with an increased relative risk of relapse of 2.4 (P < .001), whereas 1p loss was not, despite significance on univariable analysis. Conclusion: Gain of 1q is associated with inferior survival in unilateral FHWTs and may be used to guide risk stratification in future studies.

Original languageEnglish (US)
Pages (from-to)3189-3194
Number of pages6
JournalJournal of Clinical Oncology
Volume34
Issue number26
DOIs
StatePublished - Sep 10 2016

Fingerprint

Wilms Tumor
Disease-Free Survival
Histology
Chromosomes
Survival
Loss of Heterozygosity
Multiplex Polymerase Chain Reaction
Microsatellite Repeats
Neoplasms
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gratias, Eric J. ; Dome, Jeffrey S. ; Jennings, Lawrence J ; Chi, Yueh Yun ; Tian, Jing ; Anderson, James ; Grundy, Paul ; Mullen, Elizabeth A. ; Geller, James I. ; Fernandez, Conrad V. ; Perlman, Elizabeth J. / Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor : A report from the Children's Oncology Group. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 26. pp. 3189-3194.
@article{0790654e53ed4fc1ab86ee83b6a8b6ef,
title = "Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor: A report from the Children's Oncology Group",
abstract = "Purpose: The goal of this study was to analyze the association of copy number gain of 1q in favorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) within each tumor stage and with 1p and 16q copy number loss and/or loss of heterozygosity. Methods: Unilateral FHWTs from 1,114 patients enrolled in National Wilms Tumor Study-5 that were informative for 1p and 16q microsatellite markers (previously determined) and informative for 1q gain, 1p loss, and 16q loss using multiplex ligation-dependent probe amplification were analyzed. Results: Eight-year EFS was 86{\%} (95{\%} CI, 84{\%} to 88{\%}) for the entire cohort. Of 1,114 patients, 317 tumors (28{\%}) displayed 1q gain. Eight-year EFS was 77{\%} for those with 1q gain and 90{\%} for those lacking 1q gain (P < .001). Eight-year OS was 88{\%} for those with 1q gain and 96{\%} for those lacking 1q gain (P < .001). Within each disease stage, 1q gain was associated with inferior EFS (stage I, 85{\%} v 95{\%}; P = .0052; stage II, 81{\%} v 87{\%}; P = .0775; stage III, 79{\%} v 89{\%}; P = .01; stage IV, 64{\%} v 91{\%}; P = .001). OS was significantly inferior in patients with stage I (P < .0015) and stage IV disease (P = .011). With multivariable analysis, 1q gain was associated with an increased relative risk of relapse of 2.4 (P < .001), whereas 1p loss was not, despite significance on univariable analysis. Conclusion: Gain of 1q is associated with inferior survival in unilateral FHWTs and may be used to guide risk stratification in future studies.",
author = "Gratias, {Eric J.} and Dome, {Jeffrey S.} and Jennings, {Lawrence J} and Chi, {Yueh Yun} and Jing Tian and James Anderson and Paul Grundy and Mullen, {Elizabeth A.} and Geller, {James I.} and Fernandez, {Conrad V.} and Perlman, {Elizabeth J}",
year = "2016",
month = "9",
day = "10",
doi = "10.1200/JCO.2015.66.1140",
language = "English (US)",
volume = "34",
pages = "3189--3194",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "26",

}

Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor : A report from the Children's Oncology Group. / Gratias, Eric J.; Dome, Jeffrey S.; Jennings, Lawrence J; Chi, Yueh Yun; Tian, Jing; Anderson, James; Grundy, Paul; Mullen, Elizabeth A.; Geller, James I.; Fernandez, Conrad V.; Perlman, Elizabeth J.

In: Journal of Clinical Oncology, Vol. 34, No. 26, 10.09.2016, p. 3189-3194.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor

T2 - A report from the Children's Oncology Group

AU - Gratias, Eric J.

AU - Dome, Jeffrey S.

AU - Jennings, Lawrence J

AU - Chi, Yueh Yun

AU - Tian, Jing

AU - Anderson, James

AU - Grundy, Paul

AU - Mullen, Elizabeth A.

AU - Geller, James I.

AU - Fernandez, Conrad V.

AU - Perlman, Elizabeth J

PY - 2016/9/10

Y1 - 2016/9/10

N2 - Purpose: The goal of this study was to analyze the association of copy number gain of 1q in favorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) within each tumor stage and with 1p and 16q copy number loss and/or loss of heterozygosity. Methods: Unilateral FHWTs from 1,114 patients enrolled in National Wilms Tumor Study-5 that were informative for 1p and 16q microsatellite markers (previously determined) and informative for 1q gain, 1p loss, and 16q loss using multiplex ligation-dependent probe amplification were analyzed. Results: Eight-year EFS was 86% (95% CI, 84% to 88%) for the entire cohort. Of 1,114 patients, 317 tumors (28%) displayed 1q gain. Eight-year EFS was 77% for those with 1q gain and 90% for those lacking 1q gain (P < .001). Eight-year OS was 88% for those with 1q gain and 96% for those lacking 1q gain (P < .001). Within each disease stage, 1q gain was associated with inferior EFS (stage I, 85% v 95%; P = .0052; stage II, 81% v 87%; P = .0775; stage III, 79% v 89%; P = .01; stage IV, 64% v 91%; P = .001). OS was significantly inferior in patients with stage I (P < .0015) and stage IV disease (P = .011). With multivariable analysis, 1q gain was associated with an increased relative risk of relapse of 2.4 (P < .001), whereas 1p loss was not, despite significance on univariable analysis. Conclusion: Gain of 1q is associated with inferior survival in unilateral FHWTs and may be used to guide risk stratification in future studies.

AB - Purpose: The goal of this study was to analyze the association of copy number gain of 1q in favorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) within each tumor stage and with 1p and 16q copy number loss and/or loss of heterozygosity. Methods: Unilateral FHWTs from 1,114 patients enrolled in National Wilms Tumor Study-5 that were informative for 1p and 16q microsatellite markers (previously determined) and informative for 1q gain, 1p loss, and 16q loss using multiplex ligation-dependent probe amplification were analyzed. Results: Eight-year EFS was 86% (95% CI, 84% to 88%) for the entire cohort. Of 1,114 patients, 317 tumors (28%) displayed 1q gain. Eight-year EFS was 77% for those with 1q gain and 90% for those lacking 1q gain (P < .001). Eight-year OS was 88% for those with 1q gain and 96% for those lacking 1q gain (P < .001). Within each disease stage, 1q gain was associated with inferior EFS (stage I, 85% v 95%; P = .0052; stage II, 81% v 87%; P = .0775; stage III, 79% v 89%; P = .01; stage IV, 64% v 91%; P = .001). OS was significantly inferior in patients with stage I (P < .0015) and stage IV disease (P = .011). With multivariable analysis, 1q gain was associated with an increased relative risk of relapse of 2.4 (P < .001), whereas 1p loss was not, despite significance on univariable analysis. Conclusion: Gain of 1q is associated with inferior survival in unilateral FHWTs and may be used to guide risk stratification in future studies.

UR - http://www.scopus.com/inward/record.url?scp=84989934577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989934577&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.66.1140

DO - 10.1200/JCO.2015.66.1140

M3 - Article

C2 - 27400937

AN - SCOPUS:84989934577

VL - 34

SP - 3189

EP - 3194

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 26

ER -